SCHEMBL20767904

SCHEMBL20767904

CC(C)(C)OC(=O)N1CCN(c2nc3cccc(F)c3s2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 2/20 0.59
MAPT P10636 4/20 0.50
TP53 P04637 3/20 0.50
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
GPR119 Q8TDV5 4/20 0.48
GBA1 P04062 2/20 0.46
CKS1B P61024 1/20 0.44
SKP1 P63208 1/20 0.44
SKP2 Q13309 1/20 0.44
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HSD17B10 Q99714 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CXCR2 P25025 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20767907 0.89 NPC1 (0.50) NAAAMAPTTP53NPC1RAB9A
SCHEMBL20767864 0.87 NPC1 (0.47) NAAAMAPTTP53NPC1RAB9A
SCHEMBL20767921 0.87 NPC1 (0.48) NAAAMAPTTP53NPC1RAB9A
SCHEMBL20767902 0.84 NPC1 (0.48) NAAAMAPTTP53NPC1RAB9A
SCHEMBL20767946 0.82 MAPT (0.74) MAPTTP53NPC1RAB9AGPR119
SCHEMBL10219244 0.81 NPC1 (0.72) NAAAMAPTTP53NPC1RAB9A
SCHEMBL20767870 0.80 GPR119 (0.42) NAAAMAPTTP53NPC1RAB9A
SCHEMBL20767918 0.79 DTYMK (0.52) MAPTNPC1RAB9AGPR119GBA1
SCHEMBL25337035 0.78 DDB1 (0.46) NAAANPC1RAB9AGPR119GBA1
SCHEMBL29506979 0.78 DDB1 (0.46) NAAANPC1RAB9AGPR119GBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10221168-B1 Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof Wu, Xiao Hua (US) 2019-03-05 US disclosed
US-10221168-B1 Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof Wu, Xiao Hua (US) 2019-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10221168-B1 Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof MAN2A1, MAN1B1, ALG1 NAAA 3046/4885MAPT 3316/4885TP53 2387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.